What this is
- How it works
- How it works isn't classified yet
- Tested for
- Cystic Fibrosis
- Main trialPhase 1
- “This is a 3-part, single-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part A) and multiple-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part B), and a Phase 1b open-label study in subjects with CF (Part C) to assess the safety, tolerability, PK, and preliminary efficacy of ABCI. Subjects will be evaluated for eligibility during Screening within 30 days prior to Day 1 (Randomization; Visit 3). In Parts A and B, eligible healthy volunteers may be enrolled in the study and randomly allocated…”In the company’s words, NCT05802264 on ClinicalTrials.gov
Other drugs for Cystic Fibrosis
- ELX/TEZ/IVAVertex Pharmaceuticals · Phase 3
- IvacaftorVertex Pharmaceuticals · Phase 3
- VNZ/TEZ/D-IVAVertex Pharmaceuticals · Phase 3
- RCT2100ReCode Therapeutics · Phase 2
- SP-101Spirovant Sciences, Inc. · Phase 1/2
- 4D-7104D Molecular Therapeutics · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Dec 2025 | Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026